We hear the wilderness and it hears us.

Shares of Nektar Therapeutics (NASDAQ:NKTR) added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

This information was highlighted following a recent meeting between Oppenheimer analysts and Veru's management in San Francisco, which increased their confidence in the trial's success.

The Trials of J. Robert Oppenheimer: Teaser Oppenheimer was tasked with the development of the atomic bomb during World War II. The Trials of J. Robert Oppenheimer | Primary Source ...

Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform and removed the firm’s price target on the shares after the company announced ...

Cillian Murphy plays J. Robert Oppenheimer, "the father of the atomic bomb," in the 2023 film Stephanie Kaloi is a contributing writer at PEOPLE. She has been working at PEOPLE since 2022.

Oppenheimer analyst Matthew Biegler says Olema Oncology (OLMA) published a revised corporate deck today which included an update from the palazestrant plus ribociclib combination trial.

Annovis Bio's CEO to present at Oppenheimer's conference, discussing Phase 3 trial progress and NDA initiatives for buntanetap. Annovis Bio Inc. has announced that its CEO, Dr. Maria Maccecchini ...

added ~9% in the premarket on Friday after Oppenheimer upgraded the biopharma to Outperform from Perform, citing a favorable valuation setup ahead of a mid-stage trial readout for its eczema ...